Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Sarcoma 26Glioblastoma 25Gliosarcoma 22Rhabdomyosarcoma 21Sarcoma, Ewing 18Glioma 15Brain Neoplasms 14Astrocytoma 13Neuroblastoma 12Central Nervous System Neoplasms 12Oligodendroglioma 9Osteosarcoma 8Neoplasms 7Medulloblastoma 6Pancreatic Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Neoplasm Metastasis 5Breast Neoplasms 5Colorectal Neoplasms 4Bone Neoplasms 4Stomach Neoplasms 3Recurrence 3Optic Nerve Glioma 3Malignant mesenchymal tumor 3Diffuse Intrinsic Pontine Glioma 3Colonic Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rhabdoid Tumor 2

Interventions

Ifosfamide 5Filgrastim 5Doxorubicin 5Gemcitabine 4Docetaxel 4Radiotherapy 3Proton Therapy 3Carboplatin 3regorafenib 2ivosidenib 2enasidenib 2belinostat 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immune Checkpoint Inhibitors 2HhAntag691 2Fluorouracil 2Etoposide 2Epirubicin 2Cyclophosphamide 2Cisplatin 2Chemotherapy, Adjuvant 2Celecoxib 2Bevacizumab 2venetoclax 1toripalimab 1temsirolimus 1tazemetostat 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × Irinotecan × Sarcoma × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡